StockNews.com Initiates Coverage on Chimerix (NASDAQ:CMRX)

StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a research note published on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on CMRX. HC Wainwright reissued a “neutral” rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Wedbush reissued a “neutral” rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Trading Up 0.1 %

CMRX stock opened at $8.51 on Friday. The firm has a 50 day simple moving average of $5.55 and a 200-day simple moving average of $2.96. The company has a market capitalization of $765.36 million, a P/E ratio of -9.05 and a beta of 0.32. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.53.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. On average, research analysts predict that Chimerix will post -0.99 EPS for the current year.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 20,760 shares of company stock valued at $91,175 in the last quarter. Insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

A number of institutional investors and hedge funds have recently made changes to their positions in CMRX. Deerfield Management Company L.P. Series C acquired a new position in Chimerix during the 4th quarter valued at approximately $13,124,000. Rosalind Advisors Inc. bought a new stake in Chimerix in the fourth quarter valued at $10,614,000. Millennium Management LLC boosted its holdings in shares of Chimerix by 6.8% during the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after acquiring an additional 161,795 shares during the period. Marshall Wace LLP grew its position in shares of Chimerix by 1,318.5% during the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock worth $7,705,000 after acquiring an additional 2,057,864 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new position in shares of Chimerix during the fourth quarter worth about $7,169,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.